Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: Their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals

Immune checkpoint proteins including programmed cell death protein 1 (PD-1), its ligand PD-L1 and cytotoxic T lymphocyte-associated antigen-4 (CTLA‐4) are involved in proliferation, angiogenesis, metastasis, chemoresistance via immune escape and immune tolerance by disturbing cytotoxic T cell activa...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in cancer biology 2022-11, Vol.86 (Pt 3), p.1033-1057
Main Authors: Lee, Dae Young, Im, Eunji, Yoon, Dahye, Lee, Young-Seob, Kim, Geum-Soog, Kim, Donghwi, Kim, Sung-Hoon
Format: Article
Language:English
Subjects:
B7-H1 Antigen
Blood Platelets - metabolism
Clinical implications
Forkhead Transcription Factors
Humans
Immune Checkpoint Inhibitors - pharmacology
Immune Checkpoint Inhibitors - therapeutic use
Immune Checkpoint Proteins
Neoplasms - drug therapy
Phytochemicals
Phytochemicals - pharmacology
Phytochemicals - therapeutic use
Platelets
Programmed Cell Death 1 Receptor
Signaling networks
Tregs
Tumor Microenvironment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint proteins including programmed cell death protein 1 (PD-1), its ligand PD-L1 and cytotoxic T lymphocyte-associated antigen-4 (CTLA‐4) are involved in proliferation, angiogenesis, metastasis, chemoresistance via immune escape and immune tolerance by disturbing cytotoxic T cell activation. Though many clinical trials have been completed in several cancers by using immune checkpoint inhibitors alone or in combination with other agents to date, recently multi-target therapy is considered more attractive than monotherapy, since immune checkpoint proteins work with other components such as surrounding blood vessels, dendritic cells, fibroblasts, macrophages, platelets and extracellular matrix within tumor microenvironment. Thus, in the current review, we look back on research history of immune checkpoint proteins and discuss their associations with platelets or tumor cell induced platelet aggregation (TCIPA) and FOXP3+ regulatory T cells (Tregs) related molecules involved in immune evasion and tumor progression, clinical implications of completed trial results and signaling networks by phytochemicals for combination therapy with immune checkpoint inhibitors and suggest future research perspectives.
ISSN:1044-579X
1096-3650
DOI:10.1016/j.semcancer.2020.12.001